13F Holdings
中文EN

GELS Gelteq Ltd IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1920092 · Reporting currency AUD · Fiscal year ends 06/30

Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-87.4%
TTM EPS YoY-63.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin30.3%
Operating margin-3,317.7%
Net margin-4,011.9%
FCF margin-3,335.3%
EBITDA margin-2,579.4%

Returns

ROE-43.0%
ROA-31.5%
ROIC (approx.)-22.5%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets26.4%
Debt / equity0.27x
Current ratio0.27x
Interest coverage-2.87x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue1.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-06-30 · AUDFY20242024-06-30 · AUDFY20232023-06-30 · AUD
Income statement
Revenue165,645—79,843
Cost of revenue115,397——
Gross profit50,248——
R&D expense628,606276,057665,035
Operating income-5.50M-2.95M-3.10M
Interest expense1.92M599,494403,107
Pretax income-6.65M-3.55M-3.51M
Net income-$6.65MUSD-3.55M-3.51M
EBITDA-4.27M-1.73M-1.88M
EPS (basic)-0.72-0.44-0.44
EPS (diluted)-0.72-0.44-0.44
Balance sheet
Cash & equivalents344,64824,522399,224
Receivables459,724183,005345,291
Inventory——95,201
Current assets1.51M303,227990,974
PP&E, netmay include right-of-use assets (IFRS)15,90716,642—
Intangibles19.86M20.44M21.49M
Total assets21.48M20.76M22.49M
Current liabilities5.63M3.87M1.36M
Short-term debt4.20M2.08M5,086
Long-term debt13,5501.76M2.47M
Total debt4.22M3.84M2.48M
Total liabilities5.67M5.65M3.84M
Shareholders' equity15.80M15.11M18.66M
Net debt3.87M3.82M2.08M
Cash flow statement
Operating cash flow-5.52M-1.07M-1.77M
Capital expenditure3,1173,14934,503
Free cash flow-5.52M-1.07M-1.80M
Investing cash flow-736,839-148,170-75,931
Financing cash flow6.45M843,9392.03M
Depreciation & amortization1.22M1.21M1.23M

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.